NR4A1 and breast cancer: Patients with hormone receptor‐positive (HRpos), HER2‐negative (HER2neg) breast cancer (BC) benefit less from neoadjuvant chemotherapy (NACT) than patients with triple‐negative and HER2‐positive BC.